Magnesium Chloride Patents (Class 424/681)
  • Patent number: 11712449
    Abstract: The present disclosure relates to methods and complexes for ingestion of an elemental magnesium complex as inverted micellar nanodroplets designed to enhance uptake and cell delivery of active constituents. The complex and methods associated with delivery of the elemental magnesium complex disclosed improves many magnesium deficiencies that include cardiovascular, metabolic, neurohormonal, immune defense and repair systems, digestive, behavioral, and community risks.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: August 1, 2023
    Assignee: RMJH Holdings, LLC
    Inventor: Russell Jaffe
  • Patent number: 9867874
    Abstract: A combination of Arnica montana extract, bromelain, Calendula extract, daisy flower extract, grape seed extract, copper, and zinc for topical use that regulates skin immunomodulation.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 16, 2018
    Assignee: Evance, LLC
    Inventor: Elizabeth VanderVeer
  • Patent number: 9089602
    Abstract: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: July 28, 2015
    Assignee: REVEN PHARMACEUTICALS, INC.
    Inventors: Henk Van Wyk, Mariette Van Wyk, Trace Krebs, Peter Lange, Brian Denomme, Michael A. Volk
  • Patent number: 8999297
    Abstract: A generally non-acidic hemostatic agent, having a relatively neutral pH comprising a magnesium compound, such as a magnesium chloride, a magnesium sulfate and/or a magnesium acetate based compound. The resultant agent is generally less caustic than previous agents, when using a similar amount of active material.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: April 7, 2015
    Assignee: Inter-Med, Inc.
    Inventors: Gary J. Pond, John Baeten
  • Publication number: 20150064285
    Abstract: The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea.
    Type: Application
    Filed: March 21, 2014
    Publication date: March 5, 2015
    Applicant: Magceutics, Inc.
    Inventors: Guosong LIU, Fei Mao
  • Publication number: 20150010650
    Abstract: The invention provides methods and kits for treatment of pain or inflammation. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, an intra-articular administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Inventors: Josee Roy, William f. McKay, Jeffrey C. Marx
  • Publication number: 20140363524
    Abstract: A dialysis acid precursor assembly including a dialysis acid precursor composition of dry components including anhydrous glucose, a dry acid, a magnesium chloride 4.5-hydrate (MgCl2.4.5H2O) and a potassium salt or calcium salt, and a moisture-resistant container with a water vapor transmission rate less than 0.2 g/m2/d at 38° C./90% RH, wherein the dialysis acid precursor composition is sealed within the container.
    Type: Application
    Filed: December 11, 2012
    Publication date: December 11, 2014
    Inventors: Olof Jansson, Jens Gustafsson, Torbjorn Linden
  • Publication number: 20140341963
    Abstract: A composition comprising at least one substance coated with an agent wherein the agent forms a liquid impermeable but gas permeable layer surrounding the said substance and preventing the passage of the said substance through said coating, wherein in-use the said substance is not released into solution in the body, and wherein said substance is selected from one or more of the group consisting of calcium phosphate, sodium chloride, potassium chloride, magnesium chloride, calcium carbonate, and sodium bicarbonate for use in the treatment of osteoporosis and other bone conditions.
    Type: Application
    Filed: May 9, 2014
    Publication date: November 20, 2014
    Applicant: ActiveSignal Holding Limited
    Inventor: Ward Warren
  • Publication number: 20140342021
    Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
    Type: Application
    Filed: December 18, 2013
    Publication date: November 20, 2014
    Applicant: Magceutics, Inc.
    Inventors: Guosong Liu, Fei Mao
  • Patent number: 8883762
    Abstract: The present invention provides a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. Glucose-like degradation and hydrolysis is avoided during sterilization and storage, while maintenance of a neutral mixture pH is achieved by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0. The present invention further discloses a twin-chambered pouch consisting of a plastic pouch with at least one first chamber and a second chamber, the first single solution being included in the first chamber and the second single solution being included in the second chamber.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: November 11, 2014
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventor: Thomas Zimmeck
  • Patent number: 8858924
    Abstract: Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG). The composition may also comprise one or more active agent such as a blood flow modifier with a potential to form ionic bonds with the vessel closing agent.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: October 14, 2014
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: Josee Roy
  • Patent number: 8840933
    Abstract: The invention provides methods and kits for treatment of pain or inflammation. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, an intra-articular administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: September 23, 2014
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Josee Roy, William F. McKay, Jeffrey C Marx
  • Patent number: 8828453
    Abstract: Aspects of the invention relate to compositions comprising passiflora extracts that may improve neurological and behavioral symptoms associated with Pervasive Developmental Disorders.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: September 9, 2014
    Inventors: Betul Hatipoglu, Randolph Margrave
  • Patent number: 8828232
    Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: September 9, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Dilip H. Shah, Todd Ing
  • Patent number: 8778306
    Abstract: The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: July 15, 2014
    Inventor: Dale R. Bachwich
  • Publication number: 20140193524
    Abstract: The present invention relates to artificial seawater and its use to treat a variety of skin conditions, when that sea water has more magnesium in it than in naturally occurring seawater. The treatment of acne and the like can be improved with the product of the present invention.
    Type: Application
    Filed: March 12, 2014
    Publication date: July 10, 2014
    Inventor: Kenneth L. Willeford
  • Publication number: 20140127302
    Abstract: The disclosed analgesic pharmaceutical composition for oral administration is characterised in that it contains an opioid and a pharmaceutically admissible magnesium (II) compound, possibly along with one or more pharmaceutically admissible ancillary substances.
    Type: Application
    Filed: May 31, 2012
    Publication date: May 8, 2014
    Applicant: Warszawski Uniwersytet Medyczny
    Inventors: Magdalena Bujalska-Zadrozny, Marek Naruszewicz
  • Patent number: 8563053
    Abstract: A composition and method for treating a bone condition of an animal. The composition includes a nanoformulation of active ingredients. The active ingredients include Lepidium Sativum or other Lepidium extracts, calcium, vitamin D, and antioxidants. The method for treating a bone condition includes introducing the composition into the animal.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: October 22, 2013
    Inventors: Shaker A. Mousa, Mohammed H. Qari, Mohammed S. Ardawi
  • Patent number: 8546423
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: October 1, 2013
    Assignee: MPEX Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
  • Publication number: 20130236571
    Abstract: The present disclosure is directed to dispersions of a Dead Sea material in oil, the Dead Sea material is present in the dispersions in the form of solid nanoparticles. Further disclosed are formulations comprising the dispersions, method of treating and/or preventing diseases or disorders of the skin comprising topical application of the dispersions or formulations thereof onto a skin of a subject, method of inducing a heat sensation on the skin of a subject by topically applying the dispersions or formulations thereof onto a skin of a subject and methods of preparing the dispersions.
    Type: Application
    Filed: March 6, 2013
    Publication date: September 12, 2013
    Applicants: Dead Sea Laboratories Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Shlomo MAGDASSI, Liraz LARUSH, Chani MENDELSON, Miriam ORON, Zeevi MAOR, Isabelle Rachel AFRIAT-STALOFF, Marina PRIVOROTSKI
  • Patent number: 8524734
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: September 3, 2013
    Assignee: MPEX Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
  • Patent number: 8524735
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: September 3, 2013
    Assignee: MPEX Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
  • Patent number: 8414768
    Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: April 9, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Dilip H. Shah, Todd Ing
  • Patent number: 8357696
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: January 22, 2013
    Assignee: Mpex Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny, David C. Griffith
  • Publication number: 20130004589
    Abstract: Compositions and methods for treating and/or preventing conditions such as diaper rash and atopic dermatitis are disclosed. The compositions and methods are particularly useful in the treatment and prevention of diaper rash and diaper dermatitis caused by the prolonged contact of human skin with body waste. The methods employ the topical application of a trypsin-inhibiting agent to the area in need of such treatment, or the area where prevention is desired. The trypsin-inhibiting agent is preferably a divalent cation/anion pair.
    Type: Application
    Filed: June 28, 2011
    Publication date: January 3, 2013
    Inventors: Connie B. Lin, Euen Thomas Graham Ekman Gunn, Ya-Ping Hu, Neema Kulkarni, Mary Catherine Mack
  • Patent number: 8273378
    Abstract: Dialysis solutions comprising pyrophosphates and methods of making and using the dialysis solutions are provided. In an embodiment, the present disclosure provides a dialysis solution comprising a stable and therapeutically effective amount of pyrophosphate. The dialysis solution can be sterilized, for example, using a technique such as autoclave, steam, high pressure, ultra-violet, filtration or combination thereof. The dialysis solution can be in the form of a concentrate.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: September 25, 2012
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Bruce L. Riser, Paul Zieske, Sujatha Karoor, Himanshu D. Patel
  • Patent number: 8216172
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolytes but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: July 10, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter C. Chang, Jean-Michel Lannoy
  • Patent number: 8202547
    Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.
    Type: Grant
    Filed: January 17, 2011
    Date of Patent: June 19, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Dilip H. Shah, Todd Ing
  • Patent number: 8158157
    Abstract: A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: April 17, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Peter C. Chang, Jean-Michael Lannoy
  • Patent number: 8142799
    Abstract: A practical high potency anti-craving medication is disclosed which comprises three components: an amino-acid component, a vitamin component, and a mineral component, wherein each component is selected for maximum efficacy in the body of an individual suffering from substance abuse disorder as opposed to the body of a healthy individual. Additionally, the active agents are received by means of a prolonged administration, preferably by means of an IV drip, thus assuring a period of time in which the active agents are present in desired concentrations, and more preferably a prolonged time during which they are simultaneously present in desired concentrations. The agents of each component are also selected so as to allow easy administration of the medication to patients in three vials of medication rather than as a large number of individual vials.
    Type: Grant
    Filed: August 20, 2005
    Date of Patent: March 27, 2012
    Inventors: Tamea Rae Sisco, Keith Kenneth Skinner, Theodore R Keller
  • Patent number: 8142800
    Abstract: A practical high potency anti-craving oral medication or combined oral/IV drip medication is disclosed which comprises three components: a group of amino-acid substances, a group of vitamin substances, and a group of minerals, wherein each substance is selected for maximum efficacy in the body of an individual suffering from substance abuse disorder as opposed to the body of a healthy individual. The ingredients of the invention are selected to cooperate in easing metabolization in the bodies of individuals suffering the various medical conditions associated with substance abuse. The ingredients are provided orally to ease administration and to provide convenient use by patients: the oral medication may be a maintenance dosage or a corrective dosage.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: March 27, 2012
    Inventors: Tamea Rae Sisco, Keith Kenneth Skinner, Theodore Keller
  • Patent number: 8088807
    Abstract: A microbicidal composition comprising relatively high levels of a mixture of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one; a metal nitrate; and water. The composition optionally contains magnesium chloride.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: January 3, 2012
    Assignee: Rohm and Haas Company
    Inventors: Mary Jo Bergbauer, John Vincent Berrier, Richard Walter Nichols
  • Publication number: 20110318431
    Abstract: A pharmaceutical composition containing a magnesium salt and an osmotic hypertonic agent, like a mannitol, is disclosed. Also disclosed are methods of treating individuals who have suffered a neurological insult, such as traumatic brain injury.
    Type: Application
    Filed: December 29, 2009
    Publication date: December 29, 2011
    Applicant: ENDOGENX
    Inventor: Anil Gulati
  • Publication number: 20110280958
    Abstract: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) a dithiino-tetracarboximide of formula (I) and a metal salt (B). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed. In particular the combinations according to the invention are useful to obtain plants with greener leaf color.
    Type: Application
    Filed: April 14, 2011
    Publication date: November 17, 2011
    Applicant: Bayer CropScience AG
    Inventors: Thomas Seitz, Ulrike Wachendorff-Neumann
  • Publication number: 20110268717
    Abstract: Aspects of the invention relate to compositions comprising passiflora extracts that may improve neurological and behavioral symptoms associated with Pervasive Developmental Disorders.
    Type: Application
    Filed: April 29, 2011
    Publication date: November 3, 2011
    Inventors: Betul Hatipoglu, Randolph Margrave
  • Publication number: 20110262563
    Abstract: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.
    Type: Application
    Filed: July 24, 2009
    Publication date: October 27, 2011
    Applicant: NOVENTIS, INC.
    Inventors: Henk Van Wyk, Mariette Van Wyk, Trace Krebs, Peter Lange, Brian Denomme, Michael A. Volk
  • Publication number: 20110262562
    Abstract: The invention relates to aqueous saline solutions with an osmolarity of 50 mOsm/L to 170 mOsm/L, which further include at least one membrane-weakening agent. The invention also relates to a cosmetic composition which includes one of said solutions, as well as to the use of one of said solutions to obtain a drug for treating cellulite, steatomery, and lipomas.
    Type: Application
    Filed: October 27, 2009
    Publication date: October 27, 2011
    Applicant: LIPOLYANE
    Inventors: Yves Crassas, Denis Blache
  • Publication number: 20110244058
    Abstract: The invention provides compositions and methods for treating pulmonary diseases and conditions. The provided compositions and methods utilize either low concentrations of selective ?-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for ?-2 over ?-1 adrenergic receptors or ketamine at specific pH. The compositions preferably comprise brimonidine and/or dexmedetomidine and/or ketamine.
    Type: Application
    Filed: April 13, 2011
    Publication date: October 6, 2011
    Inventor: Gerald Horn
  • Patent number: 8017160
    Abstract: Disclosed are methods and complexes for increasing magnesium uptake in mammals. Increasing magnesium uptake in mammals is accomplished by concurrently administering one or more magnesium salts with one or more quaternary amines and/or phosphatides and one or more di- or tri-carboxylic acids.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: September 13, 2011
    Inventor: Russell Jaffe
  • Publication number: 20110217358
    Abstract: The present invention provides a composition containing a) clay material with a negative surface charge; b) magnesium ions and calcium ions both either incorporated within the clay material and/or added separately; c) water and/or non-aqueous solvent; d) substantially non-cationic carrier; where i) the mean particle size of the clay material is at least 5 nm; and ii) the total molar amount of magnesium ions is higher than the total molar amount of calcium ions. The present invention further relates to the use of said composition in the manufacture of a medicament for the prophylaxis and treatment of skin diseases, skin conditions, or mucosal diseases where the formation and/or recovery of epidermal/mucosal barrier function has beneficial effects.
    Type: Application
    Filed: July 28, 2009
    Publication date: September 8, 2011
    Inventors: Attila Feleki, Theodorus A.C. Migo
  • Publication number: 20110189309
    Abstract: The present invention relates, in general, to topical medicinal formulations that provide pain relief and enhance recovery from injury. In particular, the invention relates to a topical medicinal formulation comprising 0.35 to 35% of a soluble salt of a biologically acceptable alkali metal or alkaline earth metal such as sodium, potassium, lithium, magnesium and calcium and their use in methods of treating pain or enhancing healing.
    Type: Application
    Filed: July 11, 2008
    Publication date: August 4, 2011
    Inventor: Peter O'Gorman
  • Patent number: 7976876
    Abstract: The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) a mixture of a coenzyme having reducing ability and a quinone, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: July 12, 2011
    Assignee: Well-Being Biochemical Corp.
    Inventors: Jih-ru Hwu, Shwu-chen Tsay
  • Publication number: 20110151024
    Abstract: The present invention relates to compositions and methods for preventing migraines. The migraine prophylaxis composition is a single dosage form comprising at least one form of elemental magnesium and at least one NSAID. The prophylaxis composition, comprising at least one form of elemental magnesium and a therapeutically effective concentration of acetylsalicylic acid may also provide cardiac protection and prevent cardiovascular diseases.
    Type: Application
    Filed: March 1, 2011
    Publication date: June 23, 2011
    Inventor: Alexander Mauskop
  • Patent number: 7947310
    Abstract: A method for treating a patient comprising: (a) injecting into the bloodstream of a patient is breathing a gas mixture having greater than 25% oxygen an aqueous solution comprising: 0.1 to 0.8 M Mg++ and having an osmolarlity less than about 1500 mOSm/l; and (b) increasing the rate of injection at least until the patient feels a sensation of warmth is described.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: May 24, 2011
    Assignee: Relox Medical, LLC
    Inventor: Bruce Rind
  • Publication number: 20110097396
    Abstract: A cosmetic capsule which can be topically applied and rubbed in and comprises a casing material and a filling material enclosed by the casing material. The casing material is composed of an emulsion which comprises one or more waxes that are solid above 25° C. and the filling material comprising a preparation which has an abrasive effect and comprises one or more abrasive peeling agents which are present in an oil or lipid mixture, a surfactant-containing preparation or an emulsion.
    Type: Application
    Filed: September 12, 2007
    Publication date: April 28, 2011
    Inventors: Svea Wischhoefer, Nils Hoffmann, Silke Weyland, Jessica Schaefer
  • Patent number: 7910090
    Abstract: The present invention provides a base composition that allows for the formulation of non-irritating cosmetic and/or dermatological compositions. The base composition includes one or more of electrolyte, buffer, mild preservative, lubricant, or any combinations thereof. It is preferred that one or more of the above components are eye-safe and/or eye-compatible. The present invention also provides photoprotective cosmetic and/or dermatological compositions that include the base composition and one or more sunscreen active components and are non-irritating to mammalian eyes.
    Type: Grant
    Filed: January 18, 2006
    Date of Patent: March 22, 2011
    Assignee: Playtex Products, Inc.
    Inventors: Olga V. Dueva-Koganov, James P. SaNogueira
  • Patent number: 7897779
    Abstract: The present invention relates to novel 1,4-dihydropyridine derivatives, to novel cosmetic or dermatological sunscreen compositions containing these derivatives and the use of these derivatives for photoprotecting human skin and/or hair against UV radiation, in particular solar radiation.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: March 1, 2011
    Assignee: DSM IP Assets B.V.
    Inventors: Katja Berg-Schultz, Ulrich Huber, Daniel Sprenger
  • Patent number: 7883725
    Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.
    Type: Grant
    Filed: May 29, 2009
    Date of Patent: February 8, 2011
    Assignee: HHD LLC
    Inventors: Dilip H. Shah, Todd Ing
  • Publication number: 20110020443
    Abstract: The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea.
    Type: Application
    Filed: July 1, 2010
    Publication date: January 27, 2011
    Applicant: Magceutics, Inc.
    Inventors: Guosong LIU, Fei MAO
  • Patent number: 7858124
    Abstract: The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) ionic compound, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard.
    Type: Grant
    Filed: April 7, 2008
    Date of Patent: December 28, 2010
    Assignee: Well-Being Biochemical Corp.
    Inventors: Jih Ru Hwu, Shwu Chen Tsay